- Condition: Primary Hyperaldosteronism
Intervention: Procedure: 11C-Metomidate Positron Emission Tomography
Sponsors: Helsinki University Central Hospital; Helsinki University Central Hospital; Turku University Hospital; University of Tampere
Recruiting - verified March 2012 - Conditions: Adrenal Hyperplasia, Congenital; Congenital Hypothyroidism; Cystic Fibrosis
Intervention:
Sponsors: Luminex Molecular Diagnostics; Luminex Corporation
Recruiting - verified January 2012 - Condition: 21-hydroxylase Deficiency
Intervention: Drug: Abiraterone acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Addison's Disease; Adrenal Insufficiency; Diabetes Mellitus Type I
Intervention: Procedure: Spiroergometry
Sponsors: University of Wuerzburg; University of Wuerzburg
Recruiting - verified October 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Progesterone; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Metformin; Drug: Progesterone; Drug: estrace
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Flutamide; Drug: Progesterone; Drug: estrace (estradiol)
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2012 - Conditions: Adrenal Hyperplasia; Polycystic Ovarian Syndrome; Oligomenorrhea; Obesity; Hyperandrogenism
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012 - Condition: Hyperandrogenism
Intervention:
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Orlistat (Alli) and Lifestyle Intervention with exercise and diet; Drug: Loestrin 1/20; Drug: Orlistat (Alli) and Loestrin 1/20
Sponsors: Penn State University; Penn State University; University of Pennsylvania
Recruiting - verified November 2011 - Conditions: Excess Androgen; Congenital Adrenal Hyperplasia (CAH); Familial Male-Limited Precocious Puberty (FMPP)
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Conditions: Autoimmune Disease; Congenital Adrenal Hyperplasia; Healthy; Mental Disorder Diagnosed in Childhood; Neurologic Manifestations
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified September 2011
 |
Join Clinical trials for Adrenal Hyperplasia |
